

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM579934

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	SECURITY INTEREST

CONVEYING PARTY DATA

Name	Formerly	Execution Date	Entity Type
Baudax Bio N.A. LLC		05/29/2020	Limited Liability Company:
Baudax Bio Limited		05/29/2020	Unknown:
Baudax Bio, Inc.		05/29/2020	Corporation:

RECEIVING PARTY DATA

Name:	Wilmington Trust, National Association
Street Address:	1100 North Market Street
City:	Wilmington
State/Country:	DELAWARE
Postal Code:	19890
Entity Type:	National Banking Association: DELAWARE

PROPERTY NUMBERS Total: 9

Property Type	Number	Word Mark
Serial Number:	87223802	OMZUVI
Serial Number:	86861522	REXIEVE
Serial Number:	88569300	BAUDAX BIO
Serial Number:	88637939	BAUDAX BIO
Serial Number:	86861551	XOLIV
Serial Number:	87223688	ANJESO
Serial Number:	88174417	ANJESO (MELOXICAM) INJECTION
Serial Number:	87223738	OMCRYXA
Serial Number:	86861501	REXEVE

CORRESPONDENCE DATA

Fax Number: 2026626291

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: (202)662-6000

Email: greed@cov.com

Correspondent Name: Covington & Burling LLP

Address Line 1: One CityCenter, 850 Tenth Street, NW

Address Line 4: Washington, D.C. 20001

TRADEMARK

NAME OF SUBMITTER:	Genee Reed
SIGNATURE:	/Genee Reed/
DATE SIGNED:	06/05/2020

Total Attachments: 40

source=BlueBell - IP Security Agreement (Executed)#page1.tif
source=BlueBell - IP Security Agreement (Executed)#page2.tif
source=BlueBell - IP Security Agreement (Executed)#page3.tif
source=BlueBell - IP Security Agreement (Executed)#page4.tif
source=BlueBell - IP Security Agreement (Executed)#page5.tif
source=BlueBell - IP Security Agreement (Executed)#page6.tif
source=BlueBell - IP Security Agreement (Executed)#page7.tif
source=BlueBell - IP Security Agreement (Executed)#page8.tif
source=BlueBell - IP Security Agreement (Executed)#page9.tif
source=BlueBell - IP Security Agreement (Executed)#page10.tif
source=BlueBell - IP Security Agreement (Executed)#page11.tif
source=BlueBell - IP Security Agreement (Executed)#page12.tif
source=BlueBell - IP Security Agreement (Executed)#page13.tif
source=BlueBell - IP Security Agreement (Executed)#page14.tif
source=BlueBell - IP Security Agreement (Executed)#page15.tif
source=BlueBell - IP Security Agreement (Executed)#page16.tif
source=BlueBell - IP Security Agreement (Executed)#page17.tif
source=BlueBell - IP Security Agreement (Executed)#page18.tif
source=BlueBell - IP Security Agreement (Executed)#page19.tif
source=BlueBell - IP Security Agreement (Executed)#page20.tif
source=BlueBell - IP Security Agreement (Executed)#page21.tif
source=BlueBell - IP Security Agreement (Executed)#page22.tif
source=BlueBell - IP Security Agreement (Executed)#page23.tif
source=BlueBell - IP Security Agreement (Executed)#page24.tif
source=BlueBell - IP Security Agreement (Executed)#page25.tif
source=BlueBell - IP Security Agreement (Executed)#page26.tif
source=BlueBell - IP Security Agreement (Executed)#page27.tif
source=BlueBell - IP Security Agreement (Executed)#page28.tif
source=BlueBell - IP Security Agreement (Executed)#page29.tif
source=BlueBell - IP Security Agreement (Executed)#page30.tif
source=BlueBell - IP Security Agreement (Executed)#page31.tif
source=BlueBell - IP Security Agreement (Executed)#page32.tif
source=BlueBell - IP Security Agreement (Executed)#page33.tif
source=BlueBell - IP Security Agreement (Executed)#page34.tif
source=BlueBell - IP Security Agreement (Executed)#page35.tif
source=BlueBell - IP Security Agreement (Executed)#page36.tif
source=BlueBell - IP Security Agreement (Executed)#page37.tif
source=BlueBell - IP Security Agreement (Executed)#page38.tif
source=BlueBell - IP Security Agreement (Executed)#page39.tif
source=BlueBell - IP Security Agreement (Executed)#page40.tif

INTELLECTUAL PROPERTY SECURITY AGREEMENT

This INTELLECTUAL PROPERTY SECURITY AGREEMENT (as amended, restated, supplemented or otherwise modified from time to time, this “Agreement”), dated as of May 29, 2020, is by and among Borrower (as hereinafter defined); Baudax Bio N.A. LLC, a Delaware limited liability company; and Baudax Bio Limited, an Irish private company limited by shares having company number 562027 (the “Irish Guarantor”), (each a “Grantor” and, collectively, the “Grantors”) in favor of Wilmington Trust, National Association, solely in its capacity as collateral agent (together with its successors and assigns in such capacity, the “Secured Party”) for the benefit of itself and the Lenders (as hereinafter defined).

RECITALS:

WHEREAS, pursuant to that certain Credit Agreement, dated as of the date hereof (as amended, restated, supplemented and/or otherwise modified from time to time, the “Credit Agreement”), by and among Baudax Bio, Inc., a Pennsylvania corporation (the “Borrower”), the financial institutions from time to time party to the Credit Agreement as lenders (collectively, with their permitted successors and assignees, the “Lenders”), and the Secured Party, the Lenders have agreed to provide certain financial accommodations to the Borrower; and

WHEREAS, the Lenders are willing to extend financial accommodations to the Borrower as provided for in the Credit Agreement, but only upon the condition, among others, that the Grantors shall have executed and delivered to the Secured Party, for its benefit and the benefit of itself and the Lenders, this Agreement.

NOW, THEREFORE, in consideration of the premises and mutual covenants herein contained and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, each Grantor hereby agrees as follows:

SECTION 1. Defined Terms; Rules of Construction.

- (a) Capitalized terms used in this Agreement but not otherwise defined herein have the meanings given to them in the Credit Agreement.
- (b) When used herein the following terms shall have the following meanings:

“Copyrights” shall have the meaning provided thereto in the U.S. Security Agreement.

“Copyright Licenses” means all agreements pursuant to which any Grantor is licensor or licensee, granting any right under any Copyright, including but not limited to, rights to manufacture, reproduce, display, distribute, perform, modify or otherwise exploit, and sell materials embodying or derived from, any copyrighted work.

“Intellectual Property” shall have the meaning provided thereto in the U.S. Security Agreement.

“Obligations” shall have the meaning provided thereto in the Credit Agreement.

“PTO” means the United States Patent and Trademark Office and any successor office or agency.

“Patents” shall have the meaning provided thereto in the U.S. Security Agreement.

“Patent Licenses” means all agreements pursuant to which any Grantor is licensor or licensee, granting any right to manufacture, have made, import, use, or sell any invention covered in whole or in part by a Patent.

“Proceeds” shall have the meaning provided thereto in the U.S. Security Agreement.

“Products” shall have the meaning provided thereto in the Credit Agreement.

“Trademarks” shall have the meaning provided thereto in the U.S. Security Agreement.

“Trademark Licenses” mean all agreements pursuant to which any Grantor is licensor or licensee, granting any right to use a Trademark.

“UCC” shall have the meaning provided thereto in the U.S. Security Agreement.

- (c) All Schedules, Addenda, Annexes and Exhibits hereto or expressly identified to this Agreement are incorporated herein by reference and taken together with this Agreement constitute but a single agreement. The words “herein”, “hereof” and “hereunder” or other words of similar import refer to this Agreement as a whole, including the Exhibits, Addenda, Annexes and Schedules thereto, as the same may be from time to time amended, modified, restated or supplemented, and not to any particular section, subsection or clause contained in this Agreement. Wherever from the context it appears appropriate, each term stated in either the singular or plural shall include the singular and the plural, and pronouns stated in the masculine, feminine or neuter gender shall include the masculine, the feminine and the neuter. The term “or” is not exclusive. The term “including” (or any form thereof) shall not be limiting or exclusive. All references to statutes and related regulations shall include any amendments of same and any successor statutes and regulations. All references in this Agreement or in the Schedules, Addenda, Annexes and Exhibits to this Agreement to sections, schedules, disclosure schedules, exhibits, and attachments shall refer to the corresponding sections, schedules, disclosure schedules, exhibits, and attachments of or to this Agreement. All references to any instruments or agreements, including references to any of this Agreement, the Credit Agreement or the other Loan Documents shall include any and all modifications or amendments thereto and any and all extensions or renewals thereof.
- (d) The parties acknowledge that each party and its counsel have reviewed this Agreement and that the normal rule of construction to the effect that any ambiguities are to be resolved against the drafting party shall not be employed in the interpretation of this Agreement or any amendments, schedules or exhibits thereto.

SECTION 2. Grant of Security Interest in Intellectual Property Collateral. To secure the prompt payment to the Lenders of the Obligations of the Grantors now or hereafter existing from time to time, each Grantor hereby pledges and grants to the Secured Party, for its benefit and the benefit of the Lenders, a continuing security interest in and Lien upon all of such Grantor's right, title and interest in, to and under the following, whether presently existing or hereafter created or acquired (collectively, the "Collateral"):

- (a) Trademarks and Trademark Licenses to which it is a party, including those referred to on Schedule I hereto;
- (b) Patents and Patent Licenses to which it is a party, including those referred to on Schedule II hereto;
- (c) Copyrights and Copyright Licenses to which it is a party, including those referred to on Schedule III hereto;
- (d) Intellectual Property not covered by the foregoing, including those referred to on Schedule IV hereto;
- (e) Renewals, reissues, continuations, divisions, or extensions of any of the foregoing;
- (f) Rights to sue third parties for past, present or future infringement, dilution, misappropriation, or other violation of rights in any Intellectual Property, including injury to the goodwill associated with any Trademark, and all causes of action for the same; and
- (g) All Products and Proceeds of all or any of the foregoing, tort claims and all claims and other rights to payment including (i) insurance claims against third parties for loss of, damage to, or destruction of, the foregoing Collateral and (ii) payments due or to become due under licenses of any or all of the foregoing and Proceeds payable under, or unearned premiums with respect to policies of insurance in whatever form; provided, however, that the Collateral shall not constitute a grant of a security interest in any trademark or service mark applications filed in the PTO on the basis of any Grantor's intent to use such trademark or service mark, unless and until a statement of use or amendment to allege use is filed in the PTO, in which event, such trademark or service mark shall automatically be included in the Collateral.

SECTION 3. Representations and Warranties. Each Grantor represents and warrants to the Secured Party, in addition to the representations and warranties in the Credit Agreement and the other Loan Documents, that:

- (a) such Grantor has been using commercially reasonable efforts to include statutory notice of registration in connection with its use of registered Trademarks, proper marking practices in connection with the use of Patents, and appropriate notice of copyright in connection with the publication of copyrighted material;

- (b) such Grantor has used commercially reasonable efforts to ensure that all licensees of Trademarks owned by such Grantor use consistent standards of quality as directed by such Grantor in connection with its licensed products and services; and
- (c) this Agreement, together with the Security Agreement, is effective to create a valid security interest in favor of the Secured Party, for its benefit and the benefit of the Lenders, in all of such Grantor's Intellectual Property. Upon (i) the filing of this Agreement in the United States Copyright Office (with respect to the United States Copyrights set forth on Schedule III hereto), (ii) the filing of all appropriate UCC-1 financing statements (with respect to each Grantor's (A) Patents, (B) Trademarks and (C) any Copyrights of such Grantor not registered with the United States Copyright Office) (iii) the filing of this Agreement in the PTO (with respect to the United States Patents set forth on Schedule II hereto and the United States Trademarks set forth on Schedule I hereto) (iv) a Form C1 filing in respect of this Agreement with the Companies Registration Office of Ireland (v) a filing with the Revenue Commissioners of Ireland in respect of this Agreement pursuant to section 1001 of the Taxes Consolidation Act 1997 and (vi) a filing in respect of this Agreement with the Intellectual Property Office of Ireland, such security interest will be enforceable as such as against any and all creditors of, and purchasers from, such Grantor (subject only to Permitted Liens) and all action necessary to protect and perfect the Secured Party's Lien on such Grantor's Patents, Trademarks, and Copyrights, shall have been taken.

SECTION 4. Covenants. Each Grantor covenants and agrees with the Secured Party, from and after the date of this Agreement, and in addition to the covenants in the Credit Agreement and the other Loan Documents, that:

- (a) Such Grantor shall notify the Secured Party promptly in writing if it knows or has reason to know that any application or registration relating to any material Intellectual Property owned by such Grantor has or may become abandoned, dedicated to the public, placed in the public domain or otherwise invalidated or unenforceable. Such Grantor shall further notify the Secured Party promptly in writing of any adverse determination or decision in any proceeding and the institution of any proceeding challenging such Grantor before the PTO, the United States Copyright Office, or any similar agency of the United States, any State, or other country or political subdivision thereof, any internet domain registry or other registry, or any court, regarding such Grantor's ownership of or right to use, register, keep and/or maintain any material Intellectual Property. Such Grantor shall be free to prosecute and maintain its material Intellectual Property in the ordinary course of business in a commercially reasonable manner, and, notwithstanding the foregoing, shall not be required to report preliminary or initial determinations, unless and until made final (with no further right to appeal or proceed available or otherwise taken by Grantor), by the PTO, the United States Copyright Office, or any similar agency of the United States, any State, or other country or political subdivision thereof, any internet domain registry or other registry, or any court, regarding such Grantor's ownership of or right to use, register, keep and/or maintain any Intellectual Property;

- (b) Such Grantor shall (i) prosecute diligently any patent, trademark, or service mark applications pending as of the date hereof or hereafter if material to the operations of the business of such Grantor, (ii) preserve and maintain all rights in the Copyrights, Patents and Trademarks, to the extent material to the operations of the business of such Grantor and (iii) ensure that the Copyrights, Patents and Trademarks are and remain enforceable, to the extent material to the operations of the business of such Grantor. Any expenses incurred in connection with the Grantors' obligations under this Section 4(b) shall be borne by the Grantors. Except for any such items that a Grantor reasonably believes (using prudent industry customs and practices) are no longer necessary for the on-going operations of its business, the Grantors shall not abandon any material right to file a patent, trademark or service mark application, or abandon any pending patent, trademark or service mark application or any other Copyright, Patent or Trademark without the prior written consent of the Secured Party (at the direction of the Required Lenders), which consent shall not be unreasonably withheld;
- (c) In the event that any material Intellectual Property owned by or exclusively licensed to such Grantor is infringed, diluted, misappropriated, or otherwise violated by a third party, such Grantor shall notify the Secured Party promptly in writing after such Grantor learns thereof and shall promptly take all commercially reasonable actions to stop the same and enforce its rights in such material Intellectual Property and to recover all damages therefor, including, but not limited to, the initiation of a suit for injunctive relief and damages where reasonable and cost effective to do so (provided that such Grantor must initiate suit in all cases where the failure to do so could reasonably be expected to have a Material Adverse Effect) and shall take such other actions as are commercially reasonable, or as the Secured Party or the Required Lenders shall deem appropriate in its or their good faith exercise of its or their commercially reasonable discretion under the circumstances to protect such Grantor's rights in such material Intellectual Property;
- (d) Such Grantor shall use commercially reasonable efforts to use appropriate statutory notice of registration in connection with its use of registered Trademarks, proper marking practices in connection with the use of Patents, appropriate notice of copyright in connection with the publication of copyrighted materials, and other legends or markings applicable to other Intellectual Property;
- (e) Such Grantor shall use commercially reasonable efforts to maintain the level of the quality of products sold and services rendered under any Trademarks owned by such Grantor at a level at least consistent with the quality of such products and services as of the date hereof, and such Grantor shall adequately control the quality of goods and services offered by any licensees of its Trademarks;
- (f) Such Grantor shall take all steps necessary to protect the secrecy of all trade secrets material to its business
- (g) To the knowledge of such Grantor, neither the conduct of such Grantor's business nor its use of the Intellectual Property owned by such Grantor is interfering with,

infringing upon, misappropriating, or otherwise in conflict with the Intellectual Property rights of any third party; and

- (h) In the event any Grantor, (i) either directly or through any agent, employee, licensee or designee, files an application for the registration of any Patent, Trademark or Copyright with the PTO, the United States Copyright Office or any similar office or agency, (ii) obtains rights to any new patentable inventions, any registered Copyrights or any Patents or Trademarks, or (iii) becomes entitled to the benefit of any registered Copyrights or any Patents or Trademarks or any improvement on any Patent, the provisions of this Agreement shall automatically apply thereto and such Grantor shall give to the Secured Party written notice thereof by delivery of an updated Schedule III, IV, V and/or VI to the Security Agreement, as applicable, in accordance with Section 2(e) of the Security Agreement. The Grantors hereby authorize the Secured Party to modify this Agreement by amending Schedules I, II, III and IV hereto, as applicable, to include any such registered Copyrights or any such Patents and Trademarks, and to execute and deliver a supplement hereto (in form and substance satisfactory to the Secured Party and the Required Lenders) to evidence the Secured Party's lien on any such Patent, Trademark or Copyright, and the general intangibles of such Grantor relating thereto or represented thereby.

SECTION 5. Loan and Security Agreement. The security interests granted pursuant to this Agreement are granted in conjunction with the security interests granted by each Grantor to the Secured Party, for its benefit and the benefit of the Lenders pursuant to the U.S. Security Agreement. Each Grantor hereby acknowledges and affirms that the rights and remedies of the Secured Party with respect to the Collateral made and granted herein are more fully set forth in the Credit Agreement and the U.S. Security Agreement, the terms and provisions of which are incorporated by reference herein as if fully set forth herein. Any rights and remedies set forth herein are without prejudice to, and in addition to, those set forth in the Credit Agreement and the U.S. Security Agreement.

The Secured Party shall act (or omit to act) at the direction of the Required Lenders under any provision of this Agreement requiring the Secured Party to take action or to omit from taking action (other than ordinary administration) or to exercise discretion.

SECTION 6. Reinstatement. This Agreement shall remain in full force and effect and continue to be effective should any petition be filed by or against any Grantor for liquidation or reorganization, should any Grantor become insolvent or make an assignment for the benefit of any creditor or creditors or should a receiver or trustee be appointed for all or any significant part of such Grantor's assets, and shall continue to be effective or be reinstated, as the case may be, if at any time payment and performance of the Obligations, or any part thereof, is, pursuant to applicable law, rescinded or reduced in amount, or must otherwise be restored or returned by any obligee of the Obligations, whether as a "voidable preference," "fraudulent conveyance," or otherwise, all as though such payment or performance had not been made. In the event that any payment, or any part thereof, is rescinded, reduced, restored or returned, the Obligations shall be reinstated and deemed reduced only by such amount paid and not so rescinded, reduced, restored or returned.

SECTION 7. Indemnification. Each Grantor assumes all responsibility and liability arising from the use of the Intellectual Property and Grantors, jointly and severally, hereby indemnify and hold the Secured Party and the Lenders and each of the officers, directors, employees, Affiliates, controlling persons, advisors and agents of the Secured Party and the Lenders harmless from and against any claim, suit, loss, damage or expense (including reasonable attorneys' fees) arising out of any Grantor's operations of its business from the use of the Intellectual Property, except to the extent any such claim, suit, loss, damage or expense results from the Secured Party's or Lender's own gross negligence or willful misconduct, in each case as determined by a court of competent jurisdiction in a final, non-appealable determination. In any suit, proceeding or action brought by the Secured Party under any Patent License, Trademark License, or Copyright License for any sum owing thereunder, or to enforce any provisions of such License, Grantors will, jointly and severally, indemnify and keep the Secured Party and its officers, directors, employees, Affiliates, controlling persons, advisors and agents harmless from and against all expense, loss or damage suffered by reason of any defense, set off, counterclaim, recoupment or reduction or liability whatsoever of the obligee thereunder, arising out of a breach of any Grantor of any obligation thereunder or arising out of any other agreement, indebtedness or liability at any time owing to or in favor of such obligee or its successors from any Grantor, except to the extent any such expense, loss or damage results from the Secured Party's own gross negligence or willful misconduct, in each case as determined by a court of competent jurisdiction in a final, non-appealable determination, and all such obligations of Grantors shall be and remain enforceable against and only against Grantors and shall not be enforceable against the Secured Party or any Lender.

SECTION 8. Notices. Whenever it is provided herein that any notice, demand, request, consent, approval, declaration or other communication shall or may be given to or served upon any of the parties by any other party, or whenever any of the parties desires to give and serve upon any other party any communication with respect to this Agreement, each such notice, demand, request, consent, approval, declaration or other communication shall be in writing and shall be given in the manner, and deemed received, as provided for in the U.S. Security Agreement.

SECTION 9. Termination of this Agreement. Subject to Section 6 hereof, this Agreement shall terminate upon the Payment in Full in cash of all Obligations.

SECTION 10. Governing Law. THIS AGREEMENT SHALL BE GOVERNED BY AND CONSTRUED AND ENFORCED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK APPLICABLE TO CONTRACTS MADE AND PERFORMED IN SUCH STATE, WITHOUT REGARD TO PRINCIPLES OF CONFLICTS OF LAW.

SECTION 11. Electronic Signatures. The parties to this Agreement consent to the execution by or on behalf of each other party of this Agreement, and the witnessing thereof, by electronic signature, provided that such manner of execution is permitted by law. The parties to this Agreement agree that an executed copy of this Agreement may be retained in electronic form and acknowledge that such electronic form shall constitute an original of this Agreement and may be relied upon as evidence of this Agreement.

SECTION 12. Companies Registration Office of Ireland filing. By its execution of this Agreement, the Irish Guarantor irrevocably and unconditionally authorises any and each solicitor

from time to time in the Irish law firm acting for the Secured Party and the Lenders (“Lenders Solicitors”) to:

1. sign or complete (whether electronically or otherwise) on behalf of the Irish Guarantor all required security related registration forms required to be delivered to the Companies Registration Office (“CRO”) in connection with this Agreement,
2. file (whether electronically or otherwise) each such registration form with the CRO; and
3. include an email address for a solicitor in the Lenders Solicitors in each such registration form for the purposes of receiving any certificate of registration of charge electronically from the CRO.


In giving this authorisation, the Irish Guarantor agrees and acknowledges that:

1. no solicitor/client relationship exists between the Lenders Solicitors (or any solicitor at that law firm) and the Irish Guarantor;
2. it is the Irish Guarantor’s responsibility to comply with the procedures set out in Sections 409(3) and (4) of the Irish Companies Act (without prejudice to Section 410(2) thereof); and
3. the Lenders Solicitors have no liability or responsibility to the Irish Guarantor for any failure to comply with the terms of this authorisation where the Lenders Solicitors have taken all reasonably practicable steps to comply with the applicable requirements and such failure is due to anything outside the reasonable control of the Lenders Solicitors.

[Signature Pages Follow]

IN WITNESS WHEREOF, each Grantor has executed this Intellectual Property Security Agreement as of the date first written above.

BAUDAX BIO, INC.

By: 
Name: Ryan D. Lake
Title: Chief Financial Officer,
Secretary and Treasurer

BAUDAX BIO N.A. LLC

By: 
Name: Ryan D. Lake
Title: Secretary and Treasurer

BAUDAX BIO LIMITED

By: _____
Name: Gerri Henwood
Title: Director

IN WITNESS WHEREOF, each Grantor has executed this Intellectual Property Security Agreement as of the date first written above.


BAUDAX BIO, INC.

By: _____
Name: Ryan D. Lake
Title: Chief Financial Officer,
Secretary and Treasurer

BAUDAX BIO N.A. LLC


By: _____
Name: Ryan D. Lake
Title: Secretary and Treasurer

BAUDAX BIO LIMITED

By: 
Name: Gerri Henwood
Title: Director

ACCEPTED and ACKNOWLEDGED by:

WILMINGTON TRUST, NATIONAL
ASSOCIATION, as Agent

By:  _____

Name: Andrew Lennon

Title: AVP

Schedule I

Trademarks and Trademark Licenses

TRADEMARK	CTRY	APP NO	APP DATE	REG NO	REG DATE
ANJESO	AR	3575482	23-Jan-17	2938976	30-May-18
ANJESO	WP	A0064395	20-Jan-17	1339459	20-Jan-17
ANJESO	AU	IR1339459	20-Jan-17	1838224	20-Jan-17
ANJESO	CN	IR1339459	20-Jan-17	1339459	20-Jan-17
ANJESO	CO	IR1339459	20-Jan-17	1339459	20-Jan-17
ANJESO	EM	IR1339459	20-Jan-17	1339459	20-Jan-17
ANJESO	GB	IR1339459	20-Jan-17	1339459	20-Jan-17
ANJESO	IN	IR1339459	20-Jan-17	3539489	20-Jan-17
ANJESO	JP	IR1339459	20-Jan-17	1339459	20-Jan-17
ANJESO	KR	IR1339459	20-Jan-17	1339459	20-Jan-17
ANJESO	NZ	IR1339459	20-Jan-17	1064583	20-Jan-17
ANJESO	BR	912207728	25-Jan-17	912207728	21-Aug-18
ANJESO	CA	1812536	5-Dec-16	TMA1053669	11-Sep-19
ANJESO	CL	1239210	23-Jan-17	1258001	29-Aug-17
ANJESO	MX	M1829526	7-Dec-16	1743197	17-Apr-17
ANJESO	PE	691152	23-Jan-17	251551	23-Jun-17
ANJESO	ZA	2017/02075	25-Jan-17	2017/02075	19-Nov-18
ANJESO	US	87/223688	2-Nov-16		
ANJESO (stylized)	US	88/174417	30-Oct-18		
OMCRYXA	AR	3575483	23-Jan-17	2982147	16-Apr-19
OMCRYXA	WP	A0064410	20-Jan-17	1338972	20-Jan-17
OMCRYXA	AU	IR1338972	20-Jan-17	1838104	20-Jan-17
OMCRYXA	CN	IR1338972	20-Jan-17	1338972	20-Jan-17
OMCRYXA	CO	IR1338972	20-Jan-17	1338972	20-Jan-17

TRADEMARK

REEL: 006954 FRAME: 0789

TRADEMARK	CTRY	APP NO	APP DATE	REG NO	REG DATE
OMCRYXA	EM	IR1338972	20-Jan-17	1338972	20-Jan-17
OMCRYXA	GB	IR1338972	20-Jan-17	1338972	20-Jan-17
OMCRYXA	IN	IR1338972	20-Jan-17	3536712	20-Jan-17
OMCRYXA	KR	IR1338972	20-Jan-17	1338972	20-Jan-17
OMCRYXA	NZ	IR1338972	20-Jan-17	1064511	20-Jan-17
OMCRYXA	BR	912207752	25-Jan-17	912207752	21-Aug-18
OMCRYXA	CA	1812537	5-Dec-16	TMA1054143	13-Sep-19
OMCRYXA	CL	1239209	23-Jan-17	1258000	29-Aug-17
OMCRYXA	MX	M1829534	7-Dec-16	1744795	19-Apr-17
OMCRYXA	PE	691178	23-Jan-17	251552	23-Jun-17
OMCRYXA	ZA	2017/02076	25-Jan-17	2017/02076	29-Mar-19
OMCRYXA	US	87/223738	2-Nov-16		
OMZUVI	AR	3575484	23-Jan-17	2938977	30-May-18
OMZUVI	WP	A0064406	20-Jan-17	1339460	20-Jan-17
OMZUVI	AU	IR1339460	20-Jan-17	1838225	20-Jan-17
OMZUVI	CN	IR1339460	20-Jan-17	1339460	20-Jan-17
OMZUVI	CO	IR1339460	20-Jan-17	1339460	20-Jan-17
OMZUVI	EM	IR1339460	20-Jan-17	1339460	20-Jan-17
OMZUVI	GB	IR1339460	20-Jan-17	1339460	20-Jan-17
OMZUVI	IN	IR1339460	20-Jan-17	3540127	20-Jan-17
OMZUVI	JP	IR1339460	20-Jan-17	1339460	20-Jan-17
OMZUVI	KR	IR1339460	20-Jan-17	1399460	20-Jan-17
OMZUVI	NZ	IR1339460	20-Jan-17	1064584	20-Jan-17
OMZUVI	BR	912207779	25-Jan-17	912207779	21-Aug-18
OMZUVI	CA	1812539	5-Dec-16	TMA1054144	13-Sep-19
OMZUVI	CL	1239211	23-Jan-17	1258128	30-Aug-17
OMZUVI	MX	1829533	7-Dec-16	1743201	17-Apr-17
OMZUVI	PE	691151	23-Jan-17	251245	16-Jun-17
OMZUVI	ZA	2017/02077	25-Jan-17	2017/02077	29-Mar-19

TRADEMARK	CTRY	APP NO	APP DATE	REG NO	REG DATE
OMZUVI	US	87/223802	2-Nov-16		
REXEVE	AR	3492386	5-Apr-16	2979348	22-Mar-19
REXEVE	WP	A0057614	24-Mar-16	1296774	24-Mar-16
REXEVE	AU	IR1296774	24-Mar-16	1767471	24-Mar-16
REXEVE	CN	IR1296774	24-Mar-16	1296774	24-Mar-16
REXEVE	IN	IR1296774	24-Mar-16	3345230	24-Mar-16
REXEVE	JP	IR1296774	24-Mar-16	1296774	24-Mar-16
REXEVE	MX	1752288-IR1296774	24-Mar-16	1848442	20-Feb-18
REXEVE	NZ	IR1296774	24-Mar-16	1042006	24-Mar-16
REXEVE	CA	1774513	29-Mar-16	TMA1053668	11-Sep-19
REXEVE	CL	1197328	28-Mar-16	1234944	25-Jan-17
REXEVE	EM	15291081	29-Mar-16	15291081	27-Jul-16
REXEVE	PE	655862	30-Mar-16	239751	27-Jul-16
REXEVE	ZA	2016/08497	30-Mar-16	2016/08497	30-Mar-18
REXEVE	US	86/861501	30-Dec-15		
REXEVE	AR	3492387	5-Apr-16	2979349	22-Mar-19
REXEVE	WP	A0057613	24-Mar-16	1296784	24-Mar-16
REXEVE	AU	IR1296784	24-Mar-16	1767475	24-Mar-16
REXEVE	CN	IR1296784	24-Mar-16	1296784	24-Mar-16
REXEVE	CO	IR1296784	24-Mar-16	1296784	24-Mar-16
REXEVE	IN	IR1296784	24-Mar-16	3345227	24-Mar-16
REXEVE	JP	IR1296784	24-Mar-16	1296784	24-Mar-16
REXEVE	MX	IR1296784-1752291	24-Mar-16	1848443	20-Feb-18
REXEVE	NZ	IR1296784	24-Mar-16	1042009	24-Mar-16
REXEVE	CA	1774511	29-Mar-16	TMA1053667	11-Sep-19
REXEVE	CL	1197330	28-Mar-16	1235850	2-Feb-17
REXEVE	EM	15291099	29-Mar-16	15291099	20-Jul-16
REXEVE	ZA	2016/08498	30-Mar-16	2016/08498	26-Jan-18
REXEVE	US	86/861522	30-Dec-15		

TRADEMARK	CTRY	APP NO	APP DATE	REG NO	REG DATE
BAUDAX BIO	US	88/569300	07-Aug-19		
BAUDAX BIO (Stylized with Design)	US	88/637939	01-Oct-19		

Trademark	Country	Reg. No. / App. No.
XERIV	South Africa	2016/08499
XERIV	Mexico	IR1296782
XERIV	New Zealand	IR1296782
XERIV	Int'l Registration - Madrid Protocol Only	A0057610
XERIV	Japan	IR1296782
XERIV	Canada	1774501
XERIV	Brazil	910827699
XERIV	Argentina	3492389
XERIV	Australia	IR1296782
XERIV	Chile	1226226 / 1197324
XERIV	China (People's Republic)	IR1296782
XERIV	India	IR1296782
XERIV	European Union (Community)	015278351
XOLIV	European Union (Community)	015278344
XOLIV	India	IR1296783
XOLIV	Colombia	IR1296783
XOLIV	Chile	1197326
XOLIV	China (People's Republic)	IR1296783
XOLIV	Australia	IR1296783
XOLIV	Argentina	2887224 / 3492388
XOLIV	Brazil	910827753
XOLIV	Canada	1774508
XOLIV	Japan	IR1296783

Trademark	Country	Reg. No. / App. No.
XOLIV	Int'l Registration - Madrid Protocol Only	A0057612
XOLIV	New Zealand	IR1296783
XOLIV	Mexico	IR1296783
XOLIV	Korea, Republic of	IR1296783
XOLIV	South Africa	2016/08500
XOLIV	United States of America	86/861,551

Trademark Licenses

1. Asset Transfer and License Agreement, dated as of April 10, 2015, by and between Alkermes Pharma Ireland Limited and DV Technology LLC.
 - a. First Amendment to Asset Transfer and License Agreement, dated December 23, 2015.
 - b. Second Amendment to Asset Transfer and License Agreement, dated December 20, 2018.

Schedule II

Patents and Patent Licenses

Docket No. Country	Serial No. Pub. No. Patent No.	Filing Date Pub. Date Issue Date	Title	Owner/Assignee	Status
001 FAMILY					
189109,00100 (3001) United States Dex-SL	61/178,730	5/15/09	Sublingual Dexmedetomidine Spray Compositions And Methods Of Use Thereof	Baudax Bio, Inc.	Expired
189109,00101 (3002) United States Dex-SL	12/781,628 2011-0021588	5/17/10 1/27/11	Oral Mucosal Dexmedetomidine Compositions And Methods Of Use Thereof	Baudax Bio, Inc.	Abandoned
189109,00111 (3003) United States Dex-SL	15/424,923	2/6/17	Oral Mucosal Dexmedetomidine Compositions And Methods Of Use Thereof	Baudax Bio, Inc.	Abandoned
189109,00102 (3004) PCT Dex-SL	PCT/US10/35136 WO 10/132882 WO 10/132882 WO 10/132882	5/17/10 11/18/10 3/31/11 12/29/11	Sublingual Dexmedetomidine Compositions And Methods Of Use Thereof	Baudax Bio, Inc.	Expired
189109,00103 (3005) Europe Dex-SL	10775671.0 EP2429521 EP2429521	5/17/10 3/21/12 10/18/17	Sublingual Dexmedetomidine Compositions And Methods Of Use Thereof	Baudax Bio, Inc.	Issued Expires 5/17/30
189109,00113 (3313) Europe Dex-SL	17187813.5 EP3305281	8/24/17 4/11/18	Sublingual Dexmedetomidine Compositions And Methods Of Use Thereof	Baudax Bio, Inc.	Abandoned
189109,00104 (3006) Japan Dex-SL	2012-5111068 2012-526854 6172938	11/14/11 11/1/12 7/14/17	Sublingual Dexmedetomidine Compositions And Methods Of Use Thereof	Baudax Bio, Inc.	Issued Expires 5/17/30
189109,00114 (3007) Japan Dex-SL	2015-179975 2016-029055	9/11/15 3/3/16	Sublingual Dexmedetomidine Compositions And Methods Of Use Thereof	Baudax Bio, Inc.	Abandoned

Docket No. Country	Serial No. Pub. No. Patent No.	Filing Date Pub. Date Issue Date	Title	Owner/Assignee	Status
189109,00105 (3008) Australia Dex-SL	2010248776 2010248776	5/17/10 9/19/13	Sublingual Dexmedetomidine Spray Compositions And Methods Of Use Thereof	Baudax Bio, Inc.	Issued Expires 5/17/30
189109,00106 (3009) Brazil Dex-SL	PI 1010567-0 2358	11/16/11 3/15/16	Sublingual Dexmedetomidine Spray Compositions And Methods Of Use Thereof	Baudax Bio, Inc.	Abandoned
189109,00107 (3010) Canada Dex-SL	2,762,107	11/15/11	Sublingual Dexmedetomidine Compositions And Methods Of Use Thereof	Baudax Bio, Inc.	Abandoned
189109,00108 (3011) Chile Dex-SL	02858-2011 Published	11/14/11 6/22/12	Sublingual Dexmedetomidine Spray Compositions And Methods Of Use Thereof	Baudax Bio, Inc.	Abandoned
189109,00109 (3012) China Dex-SL	201080021182.0 CN102639131A	11/15/11 8/15/12	Sublingual Dexmedetomidine Spray Compositions And Methods Of Use Thereof	Baudax Bio, Inc.	Abandoned
189109,00115 (3013) Colombia Dex-SL	11-155150 767	11/15/11 6/15/12	Oral, Transmucosal Pharmaceutical Composition Comprising Dexmedetomidine	Baudax Bio, Inc.	Abandoned
189109,00116 (3014) Costa Rica Dex-SL	2011-0596	11/14/11	Sublingual Dexmedetomidine Spray Compositions And Methods Of Use Thereof	Baudax Bio, Inc.	Abandoned
189109,00117 (3015) Dominican Republic Dex-SL	P2011-0354 Published	11/14/11 7/15/12	Sublingual Dexmedetomidine Spray Compositions And Methods Of Use Thereof	Baudax Bio, Inc.	Abandoned
189109,00118 (3016) Ecuador Dex-SL	SP-11-11459 Pub	11/14/11 1/31/12	Sublingual Dexmedetomidine Spray Compositions And Methods Of Use Thereof	Baudax Bio, Inc.	Abandoned
189109,00119 (3017) Egypt Dex-SL	1927/2011	11/14/11	Sublingual Dexmedetomidine Spray Compositions And Methods Of Use Thereof	Baudax Bio, Inc.	Abandoned
189109,00125 (3018) Dex-SL	2011-003011	11/14/11	Sublingual Dexmedetomidine Spray Compositions And Methods Of Use Thereof	Baudax Bio, Inc.	Abandoned

Docket No. Country	Serial No. Pub. No. Patent No.	Filing Date Pub. Date Issue Date	Title	Owner/Assignee	Status
Honduras Dex-SL	5656	5/6/15			
189109,00126 (3019) India Dex-SL	9629/DELNP/2011 P2011-0354	8/12/11 7/15/12	Sublingual Dexmedetomidine Compositions And Methods Of Use Thereof	Baudax Bio, Inc.	Abandoned
189109,00127 (3020) Indonesia Dex-SL	W00201104163 2014/04461 IDP000049660	11/14/11 11/6/14 2/15/18	Sublingual Dexmedetomidine Spray Compositions And Methods Of Use Thereof	Baudax Bio, Inc.	Abandoned
189109,00128 (3021) Israel Dex-SL	216159 216159	11/6/11 1/30/16	Oral Transmucosal Dexmedetomidine Compositions, Delivery Device Comprising The Same And Use Thereof In The Preparation Of Medicaments For Treating Pain Without Sedation	Baudax Bio, Inc.	Issued Expires 5/17/30
189109,00129 (3022) South Korea Dex-SL	10-2011-7027466 10-1859486	11/18/11 5/14/18	Sublingual Dexmedetomidine Spray Compositions And Methods Of Use Thereof	Baudax Bio, Inc.	Issued Expires 5/17/30
189109,00135 (3023) Mexico Dex-SL	2011/011950 333985	11/10/11 10/13/15	Sublingual Dexmedetomidine Spray Compositions And Methods Of Use Thereof	Baudax Bio, Inc.	Issued Expires 5/17/30
189109,00136 (3024) New Zealand Dex-SL	596976 596976	12/8/11 9/2/14	Sublingual Dexmedetomidine Spray Compositions And Methods Of Use Thereof	Baudax Bio, Inc.	Issued Expires 5/17/30
189109,00137 (3025) Peru Dex-SL	1958-2011 1958-2011	11/14/11 7/8/12	Sublingual Dexmedetomidine Spray Compositions And Methods Of Use Thereof	Baudax Bio, Inc.	Abandoned
189109,00138 (3026) Philippines Dex-SL	1-2011-502387	11/15/11	Sublingual Dexmedetomidine Spray Compositions And Methods Of Use Thereof	Baudax Bio, Inc.	Abandoned
189109,00139 (3027) Russia Dex-SL	2011151059 2011151059 2572692	12/14/11 6/20/13 12/14/15	Sublingual Dexmedetomidine Spray Compositions And Methods Of Use Thereof	Baudax Bio, Inc.	Issued Expires 5/17/30
189109,00145 (3028) Singapore	201108266-6 175979	11/9/11 9/23/14	Sublingual Dexmedetomidine Compositions And Methods Of Use Thereof	Baudax Bio, Inc.	Issued Expires 5/17/30

Docket No. Country	Serial No. Pub. No. Patent No.	Filing Date Pub. Date Issue Date	Title	Owner/Assignee	Status
Dex-SL					
189109,00146 (3029) Viet Nam Dex-SL	1-2011-03095 29430	11/14/11 4/25/12	Sublingual Dexmedetomidine Compositions And Methods Of Use Thereof	Baudax Bio, Inc.	Abandoned
189109,00147 (3030) South Africa Dex-SL	2011/08359 2011/08359	11/14/11 7/25/12	Sublingual Dexmedetomidine Compositions And Methods Of Use Thereof	Baudax Bio, Inc.	Issued Expires 5/17/30
189109,00148 (3031) Hong Kong Dex-SL	12109245.0 1168302	9/20/12 5/4/18	Sublingual Dexmedetomidine Compositions And Methods Of Use Thereof	Baudax Bio, Inc.	Issued Expires 5/17/30
189109,00155 (3033) China Dex-SL	201610753813.7 CN 106511273A	8/29/16 3/22/17	Sublingual Dexmedetomidine Spray Compositions And Methods Of Use Thereof	Baudax Bio, Inc.	Abandoned
189109,00156 (3316) Germany Dex-SL	EP2429521	10/18/17	Sublingual Dexmedetomidine Compositions And Methods Of Use Thereof	Baudax Bio, Inc.	Issued Expires 5/17/30
189109,00157 (3317) France Dex-SL	EP2429521	10/18/17	Sublingual Dexmedetomidine Compositions And Methods Of Use Thereof	Baudax Bio, Inc.	Issued Expires 5/17/30
189109,00158 (3318) Great Britain Dex-SL	EP2429521	10/18/17	Sublingual Dexmedetomidine Compositions And Methods Of Use Thereof	Baudax Bio, Inc.	Issued Expires 5/17/30
189109,00159 (3319) Ireland Dex-SL	EP2429521	10/18/17	Sublingual Dexmedetomidine Compositions And Methods Of Use Thereof	Baudax Bio, Inc.	Issued Expires 5/17/30

Docket No. Country	Serial No. Pub. No. Patent No.	Filing Date Pub. Date Issue Date	Title	Owner/Assignee	Status
002 FAMILY					

Docket No. Country	Serial No. Pub. No. Patent No.	Filing Date Pub. Date Issue Date	Title	Owner/Assignee	Status
United States	61/293,440	1/8/10	Topical Transdermal Dexmedetomidine Compositions and Methods of Use Thereof	Baudax Bio, Inc.	Expired
United States	13/520,959	12/3/12	Topical Transdermal Dexmedetomidine Compositions and Methods of Use Thereof	Baudax Bio, Inc.	Abandoned
PCT	PCT/US11/020462	1/7/11	Topical Transdermal Dexmedetomidine Compositions and Methods of Use Thereof	Baudax Bio, Inc.	Expired
Europe	11732180.2	1/7/11	Topical Transdermal Dexmedetomidine Compositions and Methods of Use Thereof	Baudax Bio, Inc.	Abandoned
Japan	2012-548137	1/7/11	Topical Transdermal Dexmedetomidine Compositions and Methods of Use Thereof	Baudax Bio, Inc.	Abandoned
Australia	2011204315	1/7/11	Topical Transdermal Dexmedetomidine Compositions and Methods of Use Thereof	Baudax Bio, Inc.	Abandoned
Canada	2786598	1/7/11	Topical Transdermal Dexmedetomidine Compositions and Methods of Use Thereof	Baudax Bio, Inc.	Abandoned
China	20118008886.9	1/7/11	Topical Transdermal Dexmedetomidine Compositions and Methods of Use Thereof	Baudax Bio, Inc.	Abandoned
Mexico	MX/A/2012/007933	1/7/11	Topical Transdermal Dexmedetomidine Compositions and Methods of Use Thereof	Baudax Bio, Inc.	Abandoned
New Zealand	601195	1/7/11	Topical Transdermal Dexmedetomidine Compositions and Methods of Use Thereof	Baudax Bio, Inc.	Abandoned
Russia	2012133969	1/7/11	Topical Transdermal Dexmedetomidine Compositions and Methods of Use Thereof	Baudax Bio, Inc.	Abandoned
Hong Kong	13105662.1	1/7/11	Topical Transdermal Dexmedetomidine Compositions and Methods of Use Thereof	Baudax Bio, Inc.	Abandoned
New Zealand	703808	1/7/11	Topical Transdermal Dexmedetomidine Compositions and Methods of Use Thereof	Baudax Bio, Inc.	Abandoned

Docket No. Country	Serial No. Pub. No. Patent No.	Filing Date Pub. Date Issue Date	Title	Owner/Assignee	Status
003 FAMILY					
United States	61/466,191	3/22/11	A Double-Blind Placebo Controlled, Crossover Evaluation of the Analgesic Effects of RECC1100 in Chronic Low Back Pain Patients	Baudax Bio, Inc.	Expired

Docket No. Country	Serial No. Pub. No. Patent No.	Filing Date Pub. Date Issue Date	Title	Owner/Assignee	Status
004 FAMILY					
189109,00400 (3034) United States Dex-IN	61/569,255	12/11/11	Intranasal Dexmedetomidine Compositions And Methods Of Use Thereof	Baudax Bio, Inc.	Expired
189109,00401 (3035) United States Dex-IN	13/711,407 2013-0178465 9,795,559	12/11/12 7/11/13 10/24/17	Intranasal Dexmedetomidine Compositions And Methods Of Use Thereof	Baudax Bio, Inc.	Issued PTA = 0 days Expires 12/1/32
189109,00411 (3315) United States Dex-IN	15/702,319 2018-0055764	9/12/17 3/1/18	Intranasal Dexmedetomidine Compositions And Methods Of Use Thereof	Baudax Bio, Inc.	Pending
189109,00402 (3036) PCT Dex-IN	PCT/US12/68988 WO 13/090278 WO 13/090278	12/11/12 6/20/13 12/24/14	Intranasal Dexmedetomidine Compositions And Methods Of Use Thereof	Baudax Bio, Inc.	Expired
189109,00403 (3037) Europe Dex-IN	12857098.3 EP2787970 EP2787970	12/11/12 10/15/14 4/11/18	Intranasal Dexmedetomidine Compositions And Methods Of Use Thereof	Baudax Bio, Inc.	Issued Expires 12/1/32
189109,00413 (3331) Europe Dex-IN	18161834.9 EP3406247	3/14/18 11/28/18	Intranasal Dexmedetomidine Compositions And Methods Of Use Thereof	Baudax Bio, Inc.	Abandoned
189109,00404 (3038) Japan Dex-IN	2014-546186 2015-513309 6268100	6/10/14 5/7/15 1/5/18	Intranasal Dexmedetomidine Compositions And Methods Of Use Thereof	Baudax Bio, Inc.	Issued Expires 12/1/32

Docket No. Country	Serial No. Pub. No. Patent No.	Filing Date Pub. Date Issue Date	Title	Owner/Assignee	Status
189109,00414 (3314) Japan Dex-IN	2017-172633 2018-030850 6505177	9/8/17 3/1/18 4/24/19	Intranasal Dexmedetomidine Compositions And Methods Of Use Thereof	Baudax Bio, Inc.	Issued Expires 12/1/32
189109,00405 (3039) Australia Dex-IN	2012352528 2012352528	12/11/12 2/8/18	Intranasal Dexmedetomidine Compositions And Methods Of Use Thereof	Baudax Bio, Inc.	Issued Expires 12/1/32
189109,00406 (3040) Brazil Dex-IN	BR1120140191719	6/9/14	Intranasal Dexmedetomidine Compositions And Methods Of Use Thereof	Baudax Bio, Inc.	Pending
189109,00407 (3041) Canada Dex-IN	2,858,721	6/9/14	Intranasal Dexmedetomidine Compositions And Methods Of Use Thereof	Baudax Bio, Inc.	Pending
189109,00408 (3042) Chile Dex-IN	2014-01515 700	6/9/14 7/21/14	Use Of 10 µg To 50 µg Of Dexmedetomidine, Or A Pharmaceutically Acceptable Salt Thereof For Preparing An Intranasal Medicament For Treating Or Preventing Pain In An Adult Human	Baudax Bio, Inc.	Pending
189109,00409 (3043) China Dex-IN	201280067920_4 CN 104470516	7/23/14 3/25/15	Intranasal Dexmedetomidine Compositions And Methods Of Use Thereof	Baudax Bio, Inc.	Abandoned
189109,00415 (3044) Colombia Dex-IN	14-143289	7/3/14	Intranasal Dexmedetomidine Compositions And Methods Of Use Thereof	Baudax Bio, Inc.	Abandoned
189109,00416 (3045) Costa Rica Dex-IN	2014-0318	7/3/14	Intranasal Dexmedetomidine Compositions And Methods Of Use Thereof	Baudax Bio, Inc.	Abandoned
189109,00417 (3046) Dominican Republic Dex-IN	P2014-0123	6/9/14	Intranasal Dexmedetomidine Compositions And Methods Of Use Thereof	Baudax Bio, Inc.	Abandoned
189109,00418 (3047) Ecuador Dex-IN	IEPI 2014-7644 609	7/3/14	Intranasal Dexmedetomidine Compositions And Methods Of Use Thereof	Baudax Bio, Inc.	Abandoned
189109,00419 (3048)	916/2014 PCT	6/9/14	Intranasal Dexmedetomidine Compositions And Methods Of Use Thereof	Baudax Bio, Inc.	Pending

Docket No. Country	Serial No. Pub. No. Patent No.	Filing Date Pub. Date Issue Date	Title	Owner/Assignee	Status
Egypt Dex-IN			Methods Of Use Thereof		
189109,00425 (3049) Honduras Dex-IN	2014-000880	6/9/14	Intranasal Dexmedetomidine Compositions And Methods Of Use Thereof	Baudax Bio, Inc.	Abandoned
189109,00426 (3050) India Dex-IN	5403/2014	7/1/14	Intranasal Dexmedetomidine Compositions And Methods Of Use Thereof	Baudax Bio, Inc.	Pending
189109,00427 (3051) Indonesia Dex-IN	P00 2014 03910 2015/05287	6/27/14 11/27/15	Intranasal Dexmedetomidine Compositions And Methods Of Use Thereof	Baudax Bio, Inc.	Abandoned
189109,00428 (3052) Israel Dex-IN	232977 232977	6/5/14 5/1/19	Intranasal Dexmedetomidine Compositions And Methods Of Use Thereof	Baudax Bio, Inc.	Issued Expires 12/1/32
189109,00429 (3053) South Korea Dex-IN	10-2014-7017624	12/11/12	Intranasal Dexmedetomidine Compositions And Methods Of Use Thereof	Baudax Bio, Inc.	Pending
189109,00435 (3054) Mexico Dex-IN	2014/006961 367286	6/10/14 8/13/19	Intranasal Dexmedetomidine Compositions And Methods Of Use Thereof	Baudax Bio, Inc.	Issued Expires 12/1/32
189109,00436 (3055) New Zealand Dex-IN	626999 626999	12/11/12 11/1/16	Intranasal Dexmedetomidine Compositions And Methods Of Use Thereof	Baudax Bio, Inc.	Issued Expires 12/1/32
189109,00437 (3056) Peru Dex-IN	924-2014	6/9/14	Intranasal Dexmedetomidine Compositions And Methods Of Use Thereof	Baudax Bio, Inc.	Abandoned
189109,00438 (3057) Philippines Dex-IN	1-2014-501273	6/5/14	Intranasal Dexmedetomidine Compositions And Methods Of Use Thereof	Baudax Bio, Inc.	Abandoned
189109,00439 (3058) Russia Dex-IN	2014128343 2014128343 2692245	7/10/14 1/27/16	Intranasal Dexmedetomidine Compositions And Methods Of Use Thereof	Baudax Bio, Inc.	Issued Expires 12/1/32

Docket No. Country	Serial No. Pub. No. Patent No.	Filing Date Pub. Date Issue Date	Title	Owner/Assignee	Status
189109,00445 (3059) Singapore Dex-IN	11201403094T	6/10/14	Intranasal Dexmedetomidine Compositions And Methods Of Use Thereof	Baudax Bio, Inc.	Abandoned
189109,00446 (3060) Viet Nam Dex-IN	1-2014-02131	6/30/14	Intranasal Dexmedetomidine Pharmaceutical Compositions And Metered Dose Devices Comprising The Same	Baudax Bio, Inc.	Abandoned
189109,00447 (3061) South Africa Dex-IN	2014/04287	6/10/14	Intranasal Dexmedetomidine Compositions And Methods Of Use Thereof	Baudax Bio, Inc.	Pending
189109,00448 (3062) Hong Kong Dex-IN	15103572.3 1203049 1203049	4/13/15 10/16/15 5/17/19	Intranasal Dexmedetomidine Compositions And Methods Of Use Thereof	Baudax Bio, Inc.	Issued Expires 12/1/32
189109,00449 (3063) Singapore Dex-IN	10201604653T	6/8/16	Intranasal Dexmedetomidine Compositions And Methods Of Use Thereof	Baudax Bio, Inc.	Abandoned
189109,00455 (3330) Australia Dex-IN	2018200591 2018200591	1/24/18 3/14/19	Intranasal Dexmedetomidine Compositions And Methods Of Use Thereof	Baudax Bio, Inc.	Issued Expires 12/1/32
189109,00456 (3337) Germany Dex-IN	EP2787970	4/11/18	Intranasal Dexmedetomidine Compositions And Methods Of Use Thereof	Baudax Bio, Inc.	Issued Expires 12/1/32
189109,00457 (3338) France Dex-IN	EP2787970	4/11/18	Intranasal Dexmedetomidine Compositions And Methods Of Use Thereof	Baudax Bio, Inc.	Issued Expires 12/1/32
189109,00458 (3339) Great Britain Dex-IN	EP2787970	4/11/18	Intranasal Dexmedetomidine Compositions And Methods Of Use Thereof	Baudax Bio, Inc.	Issued Expires 12/1/32
189109,00459 (3340) Ireland Dex-IN	EP2787970	4/11/18	Intranasal Dexmedetomidine Compositions And Methods Of Use Thereof	Baudax Bio, Inc.	Issued Expires 12/1/32
189109,00465 (3341)	EP2787970	4/11/18	Intranasal Dexmedetomidine Compositions And Methods Of Use Thereof	Baudax Bio, Inc.	Issued

Docket No. Country	Serial No. Pub. No. Patent No.	Filing Date Pub. Date Issue Date	Title	Owner/Assignee	Status
Italy Dex-IN					Expires 12/11/32

005 FAMILY

Docket No. Country	Serial No. Pub. No. Patent No.	Filing Date Pub. Date Issue Date	Title	Owner/Assignee	Status
189109,00501 (3064) United States Fado	13/096,387 2011-0294862 8,470,862	4/28/11 12/1/11 6/25/13	Treatment Of Prevention Of Hypotension And Shock	Baudax Bio, Inc.	Issued PTA = 0 days Expires 10/27/20
189109,00511 (3065) United States Fado	13/925,271 2014-0100257 9,078,883	6/24/13 4/10/14 7/14/15	Treatment Of Prevention Of Hypotension And Shock	Baudax Bio, Inc.	Issued PTA = 0 days Expires 10/27/20
189109,00521 (3066) United States Fado	14/738,717 2016-0030392 9,446,025	6/12/15 2/4/16 9/20/16	Treatment Of Prevention Of Hypotension And Shock	Baudax Bio, Inc.	Issued PTA = 0 days Expires 10/27/20
189109,00531 (3067) United States Fado	15/239,227	8/17/16	Treatment Of Prevention Of Hypotension And Shock	Baudax Bio, Inc.	Abandoned

006 FAMILY

Docket No. Country	Serial No. Pub. No. Patent No.	Filing Date Pub. Date Issue Date	Title	Assignee/Owner	Status
189109,00601 (3068) United States Fado	10/537,622 2006-0178417 7,759,496	3/29/06 8/10/06 7/20/10	Imidazol Derivatives Having Affinity For Alpha 2 Receptors Activity	Baudax Bio, Inc.	Issued PTA = 492 days Expires 4/10/25
189109,00604 (3069) Japan	2004-556387 4667042	12/5/03 1/21/11	Imidazol Derivatives Having Affinity For Alpha 2 Receptors Activity	Baudax Bio, Inc.	Issued Expires 12/5/23

Docket No. Country	Serial No. Pub. No. Patent No.	Filing Date Pub. Date Issue Date	Title	Assignee/Owner	Status
Fado					
189109,00605 (3070) Australia Fado	2003302622 2003302622 Expires 12/5/23	12/5/03 5/27/10	Imidazol Derivatives Having Affinity For Alpha 2 Receptors Activity	Baudax Bio, Inc.	Abandoned
189109,00607 (3071) Canada Fado	2,508,335 2,508,335	12/5/03 9/13/11	Imidazol Derivatives Having Affinity For Alpha 2 Receptors Activity	Baudax Bio, Inc.	Issued Expires 12/5/23
189109,00608 (3323) China Fado	200380105132.0 1735409 200380105132.0	12/5/03 2/15/06 11/18/09	Imidazol Derivatives Having Affinity For Alpha 2 Receptors Activity	Baudax Bio, Inc.	Issued Expires 12/5/23
189109,00615 (3072) Israel Fado	168882 168882 Expires 12/5/23	12/5/03 9/1/10	Imidazol Derivatives Having Affinity For Alpha 2 Receptors Activity	Baudax Bio, Inc.	Abandoned
189109,00618 (3073) Mexico Fado	2005/005963 253821 Expires 12/5/23	12/5/03 1/25/08	Imidazol Derivatives Having Affinity For Alpha 2 Receptors Activity	Baudax Bio, Inc.	Abandoned
189109,00625 (3074) New Zealand Fado	540466 540466 Expires 12/5/23	12/5/03 8/14/08	Imidazol Derivatives Having Affinity For Alpha 2 Receptors Activity	Baudax Bio, Inc.	Abandoned
189109,00626 (3075) Philippines Fado	1-2005-501062 1-2005-501062 Expires 12/5/23	12/5/03 12/4/09	Imidazol Derivatives Having Affinity For Alpha 2 Receptors Activity	Baudax Bio, Inc.	Abandoned
189109,00627 (3076) Singapore Fado	200503419.4 111885 Expires 12/5/23	12/5/03 6/29/07	Imidazol Derivatives Having Affinity For Alpha 2 Receptors Activity	Baudax Bio, Inc.	Abandoned
189109,00628 (3077) South Africa Fado	2005/04533 2005/04533 Expires 12/5/23	12/5/03 3/29/06	Imidazol Derivatives Having Affinity For Alpha 2 Receptors Activity	Baudax Bio, Inc.	Abandoned
189109,00646 (3325) Germany Fado	EP1572198	4/19/06	Imidazol Derivatives Having Affinity For Alpha 2 Receptors Activity	Baudax Bio, Inc.	Issued Expires 12/5/23

Docket No. Country	Serial No. Pub. No. Patent No.	Filing Date Pub. Date Issue Date	Title	Assignee/Owner	Status
189109,00649 (3326) Spain Fado	EP1572198	4/19/06	Imidazol Derivatives Having Affinity For Alpha 2 Receptors Activity	Baudax Bio, Inc.	Issued Expires 12/5/23
189109,00656 (3327) France Fado	EP1572198	4/19/06	Imidazol Derivatives Having Affinity For Alpha 2 Receptors Activity	Baudax Bio, Inc.	Issued Expires 12/5/23
189109,00657 (3328) Great Britain Fado	EP1572198	4/19/06	Imidazol Derivatives Having Affinity For Alpha 2 Receptors Activity	Baudax Bio, Inc.	Issued Expires 12/5/23
189109,00666 (3329) Ireland Fado	EP1572198	4/19/06	New Pharmaceutical Compounds with Alpha2Receptor Activity	Baudax Bio, Inc.	Issued Expires 12/5/23

007 FAMILY

Docket No. Country Client Ref. No..	Serial No. Pub. No. Patent No.	Filing Date Pub. Date Issue Date	Title	Owner/Assignee	Status
United States	60/004,488	9/29/95	Reduction of Intravenously Administered Nanoparticulate-Formulation Induced Adverse Physiological Reactions	Baudax Bio, Inc.	Expired
United States	08/696,754	8/14/96	Reduction of Intravenously Administered Nanoparticulate-Formulation Induced Adverse Physiological Reactions	Baudax Bio, Inc.	Expired
United States	5,834,025	11/10/98	Reduction of Intravenously Administered Nanoparticulate-Formulation Induced Adverse Physiological Reactions	Baudax Bio, Inc.	Abandoned
Europe	10181619.7	9/25/96	Reduction of Intravenously Administered Nanoparticulate-Formulation Induced Adverse Physiological Reactions	Baudax Bio, Inc.	Abandoned
Canada	2232879	9/25/96	Reduction of Intravenously Administered Nanoparticulate-Formulation Induced Adverse Physiological Reactions	Baudax Bio, Inc.	Abandoned
	2232879	3/2/04	Reduction of Intravenously Administered Nanoparticulate-Formulation Induced Adverse Physiological Reactions	Baudax Bio, Inc.	Abandoned
	12/027,100	2/6/08	Reduction of Intravenously Administered Nanoparticulate-Formulation Induced Adverse Physiological Reactions	Baudax Bio, Inc.	Abandoned

Docket No. Country Client Ref. No..	Serial No. Pub. No. Patent No.	Filing Date Pub. Date Issue Date	Title	Owner/Assignee	Status
United States	RE41884	10/26/10	Physiological Reactions		
Europe	96932321.1	9/25/96	Reduction of Intravenously Administered Nanoparticulate-Formulation Induced Adverse Physiological Reactions	Baudax Bio, Inc.	Abandoned

008 FAMILY

Docket No. Country	Serial No. Pub. No. Patent No.	Filing Date Pub. Date Issue Date	Title	Owner/Assignee	Status
189109,00800 (3078) United States Meloxicam	60353,230	2/4/02	Nanoparticulate Compositions Having Lysozyme As A Surface Stabilizer	Baudax Bio, Inc.	Expired
189109,00801 (3079) United States Meloxicam	10357,514 2003-0185869 7,459,283	2/4/03 10/2/03 12/2/08	Nanoparticulate Compositions Having Lysozyme As A Surface Stabilizer	Baudax Bio, Inc.	Issued PTA = 1252 days Expires 12/25/22
189109,00811 (3080) United States Meloxicam	12/292,091 2009-0074875 8,323,641	11/12/08 3/19/09 12/4/12	Nanoparticulate Compositions Having Lysozyme As A Surface Stabilizer Baudax Bio, Inc. (A) Recro Ireland Limited (L)	Baudax Bio, Inc.	Issued PTA = 822 days Expires 12/25/22
189109,00821 (3081) United States Meloxicam	13/693,858 2013-0224123 8,652,464	12/4/12 8/29/13 2/18/14	Method Of Treatment Using Nanoparticulate Compositions Having Lysozyme As A Surface Stabilizer	Baudax Bio, Inc.	Issued PTA = 0 days Expires 12/25/22
189109,00803 (3082) Europe Meloxicam	03737537.5 EP1471887	2/4/03 4/21/10	Nanoparticulate Compositions Having Lysozyme As A Surface Stabilizer	Baudax Bio, Inc.	Issued Expires 2/4/23
189109,00804 (3083) Japan Meloxicam	2003-565446 4598399	2/4/03 4/21/10	Nanoparticulate Compositions Having Lysozyme As A Surface Stabilizer	Baudax Bio, Inc.	Issued Expires 2/4/23
189109,00814 (3084) Japan			Nanoparticulate Compositions Having Lysozyme As A Surface Stabilizer	Baudax Bio, Inc.	Issued Expires 2/4/23

Docket No. Country	Serial No. Pub. No. Patent No.	Filing Date Pub. Date Issue Date	Title	Owner/Assignee	Status
Meloxicam 189109,00805 (3085)	2,475,092 2,475,092	2/4/03	Nanoparticulate Compositions Having Lysozyme As A Surface Stabilizer	Baudax Bio, Inc.	Issued Expires 2/4/23
Meloxicam 189109,00806 (3086)	EP1471887	4/21/10	Nanoparticulate Compositions Having Lysozyme As A Surface Stabilizer	Baudax Bio, Inc.	Abandoned
Meloxicam 189109,00807 (3087)	EP1471887	4/21/10	Nanoparticulate Compositions Having Lysozyme As A Surface Stabilizer	Baudax Bio, Inc.	Issued Expires 2/4/23
Belgium Meloxicam 189109,00808 (3088)	EP1471887	4/21/10	Nanoparticulate Compositions Having Lysozyme As A Surface Stabilizer	Baudax Bio, Inc.	Abandoned
Bulgaria Meloxicam 189109,00809 (3089)	EP1471887	4/21/10	Nanoparticulate Compositions Having Lysozyme As A Surface Stabilizer	Baudax Bio, Inc.	Abandoned
Czech Republic Meloxicam 189109,00815 (3090)	EP1471887	4/21/10	Nanoparticulate Compositions Having Lysozyme As A Surface Stabilizer	Baudax Bio, Inc.	Issued Expires 2/4/23
Denmark Meloxicam 189109,00816 (3091)	EP1471887	4/21/10	Nanoparticulate Compositions Having Lysozyme As A Surface Stabilizer	Baudax Bio, Inc.	Issued Expires 2/4/23
Finland Meloxicam 189109,00817 (3092)	EP1471887	4/21/10	Nanoparticulate Compositions Having Lysozyme As A Surface Stabilizer	Baudax Bio, Inc.	Issued Expires 2/4/23
France Meloxicam 189109,00818 (3093)	EP1471887	4/21/10	Nanoparticulate Compositions Having Lysozyme As A Surface Stabilizer	Baudax Bio, Inc.	Issued Expires 2/4/23
Germany Meloxicam 189109,00819 (3094)	EP1471887	4/21/10	Nanoparticulate Compositions Having Lysozyme As A Surface Stabilizer	Baudax Bio, Inc.	Abandoned
Greece Meloxicam					

Docket No. Country	Serial No. Pub. No. Patent No.	Filing Date Pub. Date Issue Date	Title	Owner/Assignee	Status
189109,00825 (3095) Hungary Meloxicam	EP1471887	4/21/10	Nanoparticulate Compositions Having Lysozyme As A Surface Stabilizer	Baudax Bio, Inc.	Issued Expires 2/4/23
189109,00826 (3096) Ireland Meloxicam	EP1471887	4/21/10	Nanoparticulate Compositions Having Lysozyme As A Surface Stabilizer	Baudax Bio, Inc.	Issued Expires 2/4/23
189109,00827 (3097) Italy Meloxicam	EP1471887	4/21/10	Nanoparticulate Compositions Having Lysozyme As A Surface Stabilizer	Baudax Bio, Inc.	Issued Expires 2/4/23
189109,00828 (3098) Netherlands Meloxicam	EP1471887	4/21/10	Nanoparticulate Compositions Having Lysozyme As A Surface Stabilizer	Baudax Bio, Inc.	Issued Expires 2/4/23
189109,00829 (3099) Portugal Meloxicam	EP1471887	4/21/10	Nanoparticulate Compositions Having Lysozyme As A Surface Stabilizer	Baudax Bio, Inc.	Abandoned
189109,00835 (3100) Slovakia Meloxicam	EP1471887	4/21/10	Nanoparticulate Compositions Having Lysozyme As A Surface Stabilizer	Baudax Bio, Inc.	Abandoned
189109,00836 (3101) Spain Meloxicam	EP1471887	4/21/10	Nanoparticulate Compositions Having Lysozyme As A Surface Stabilizer	Baudax Bio, Inc.	Issued Expires 2/4/23
189109,00837 (3102) Sweden Meloxicam	EP1471887	4/21/10	Nanoparticulate Compositions Having Lysozyme As A Surface Stabilizer	Baudax Bio, Inc.	Issued Expires 2/4/23
189109,00838 (3103) Switzerland Meloxicam	EP1471887	4/21/10	Nanoparticulate Compositions Having Lysozyme As A Surface Stabilizer	Baudax Bio, Inc.	Issued Expires 2/4/23
189109,00839 (3104) Great Britain Meloxicam	EP1471887	4/21/10	Nanoparticulate Compositions Having Lysozyme As A Surface Stabilizer	Baudax Bio, Inc.	Issued Expires 2/4/23

Docket No. Country	Serial No. Pub. No. Patent No.	Filing Date Pub. Date Issue Date	Title	Owner/Assignee	Status
009 FAMILY					
189109,00900 (3105) United States Meloxicam	60/450,705	3/3/03	Nanoparticulate Meloxicam Formulations	Baudax Bio, Inc.	Expired
189109,00901 (3106) United States Meloxicam	10/784,900 2004-0229038 8,512,727	2/24/04 11/18/04 8/20/13	Nanoparticulate Meloxicam Formulations	Baudax Bio, Inc.	Issued PTA = 637 days Expires 12/25/22
189109,00911 (3107) United States Meloxicam	13/941,076 2014-0141083	7/12/13 5/22/14	Nanoparticulate Meloxicam Formulations	Baudax Bio, Inc.	Abandoned
189109,00931 (3307) United States Meloxicam	15/437,534 2017-0157061 10,471,067	2/21/17 6/8/17 11/12/19	Nanoparticulate Meloxicam Formulations	Baudax Bio, Inc.	Issued PTA = 0 days Expires 2/24/24
189109,00941 (3334) United States Meloxicam	15/950,367 2018-0228809 10,463,673	4/11/18 8/16/18 11/5/19	Nanoparticulate Meloxicam Formulations	Baudax Bio, Inc.	Issued PTA = 0 days Expires 2/24/24
189109,00951 (3335) United States Meloxicam	15/950,539 2018-0228810	4/11/18 8/16/18	Nanoparticulate Meloxicam Formulations	Baudax Bio, Inc.	Abandoned
189109,00961 (3366) United States Meloxicam	16/507,796	7/20/19	Nanoparticulate Meloxicam Formulations	Baudax Bio, Inc.	Pending
189109,00971 (3368) United States Meloxicam	16/550,239 2019-0381062	8/25/19 12/19/19	Nanoparticulate Meloxicam Formulations	Baudax Bio, Inc.	Pending
189109,00903 (3108) Europe Meloxicam	04785761.0 EP1617816	2/27/04 5/13/09	Nanoparticulate Meloxicam Formulations	Baudax Bio, Inc.	Issued Expires 2/27/24
189109,00913 (3109) Europe Meloxicam	08006465.2	2/27/04	Nanoparticulate Meloxicam Formulations	Baudax Bio, Inc.	Abandoned

Docket No. Country	Serial No. Pub. No. Patent No.	Filing Date Pub. Date Issue Date	Title	Owner/Assignee	Status
189109,00923 (3110) Europe Meloxicam	16161176.9 EP3090731 EP3090731	3/18/16 11/9/16 9/19/18	Nanoparticulate Meloxicam Formulations	Baudax Bio, Inc.	Issued Expires 2/27/24
189109,00933 (3333) Europe Meloxicam	18186018.0 EP3434261	7/27/18 1/30/19	Nanoparticulate Meloxicam Formulations	Baudax Bio, Inc.	Pending
189109,00904 (3111) Japan Meloxicam	2006-532300 4891774	2/27/04 12/22/11	Nanoparticulate Meloxicam Formulations	Baudax Bio, Inc.	Issued Expires 2/27/24
189109,00914 (3112) Japan Meloxicam	2010-233858 5548092	2/27/04 7/16/14	Nanoparticulate Meloxicam Formulations	Baudax Bio, Inc.	Issued Expires 2/27/24
189109,00924 (3113) Japan Meloxicam	2011-148037 2012-012397	7/4/11 1/19/12	Nanoparticulate Meloxicam Formulations	Baudax Bio, Inc.	Pending
189109,00905 (3114) Canada Meloxicam	2,517,679 2,517,679	2/27/04	Nanoparticulate Meloxicam Formulations	Baudax Bio, Inc.	Issued Expires 2/27/24
189109,00906 (3115) Belgium Meloxicam	EP1617816	5/13/09	Nanoparticulate Meloxicam Formulations	Baudax Bio, Inc.	Issued Expires 2/27/24
189109,00907 (3116) France Meloxicam	EP1617816	5/13/09	Nanoparticulate Meloxicam Formulations	Baudax Bio, Inc.	Issued Expires 2/27/24
189109,00908 (3117) Germany Meloxicam	EP1617816	5/13/09	Nanoparticulate Meloxicam Formulations	Baudax Bio, Inc.	Issued Expires 2/27/24
189109,00909 (3118) Hungary Meloxicam	EP1617816	5/13/09	Nanoparticulate Meloxicam Formulations Baudax Bio, Inc. (A)	Baudax Bio, Inc.	Issued Expires 2/27/24
189109,00915 (3119)	EP1617816	5/13/09	Nanoparticulate Meloxicam Formulations	Baudax Bio, Inc.	Issued

Docket No. Country	Serial No. Pub. No. Patent No.	Filing Date Pub. Date Issue Date	Title	Owner/Assignee	Status
Ireland Meloxicam			Baudax Bio, Inc. (A)		Expires 2/27/24
189109,00916 (3120) Italy Meloxicam	EP1617816	5/13/09	Nanoparticulate Meloxicam Formulations	Baudax Bio, Inc.	Issued Expires 2/27/24
189109,00917 (3121) Spain Meloxicam	EP1617816	5/13/09	Nanoparticulate Meloxicam Formulations Baudax Bio, Inc. (A)	Baudax Bio, Inc.	Issued Expires 2/27/24
189109,00918 (3122) Switzerland Meloxicam	EP1617816	5/13/09	Nanoparticulate Meloxicam Formulations	Baudax Bio, Inc.	Issued Expires 2/27/24
189109,00919 (3123) Great Britain Meloxicam	EP1617816	5/13/09	Nanoparticulate Meloxicam Formulations	Baudax Bio, Inc.	Issued Expires 2/27/24
189109,00925 (3124) Hong Kong Meloxicam	17102503.7 1228765A	3/10/17 11/10/17	Nanoparticulate Meloxicam Formulations	Baudax Bio, Inc.	Issued Expires 2/27/24
189109,00926 (3351) Austria Meloxicam	EP3090731	9/19/18	Nanoparticulate Meloxicam Formulations	Baudax Bio, Inc.	Issued Expires 2/27/24
189109,00927 (3352) Belgium Meloxicam	EP3090731	9/19/18	Nanoparticulate Meloxicam Formulations	Baudax Bio, Inc.	Issued Expires 2/27/24
189109,00928 (3353) Denmark Meloxicam	EP3090731	9/19/18	Nanoparticulate Meloxicam Formulations	Baudax Bio, Inc.	Issued Expires 2/27/24
189109,00929 (3354) Finland Meloxicam	EP3090731	9/19/18	Nanoparticulate Meloxicam Formulations	Baudax Bio, Inc.	Issued Expires 2/27/24
189109,00935 (3355) France Meloxicam	EP3090731	9/19/18	Nanoparticulate Meloxicam Formulations	Baudax Bio, Inc.	Issued Expires 2/27/24

Docket No. Country	Serial No. Pub. No. Patent No.	Filing Date Pub. Date Issue Date	Title	Owner/Assignee	Status
189109,00936 (3356) Germany Meloxicam	EP3090731	9/19/18	Nanoparticulate Meloxicam Formulations	Baudax Bio, Inc.	Issued Expires 2/27/24
189109,00937 (3357) Hungary Meloxicam	EP3090731	9/19/18	Nanoparticulate Meloxicam Formulations	Baudax Bio, Inc.	Issued Expires 2/27/24
189109,00938 (3358) Ireland Meloxicam	EP3090731	9/19/18	Formulations Comprising Nanoparticulate Meloxicam	Baudax Bio, Inc.	Issued Expires 2/27/24
189109,00939 (3359) Italy Meloxicam	EP3090731	9/19/18	Nanoparticulate Meloxicam Formulations	Baudax Bio, Inc.	Issued Expires 2/27/24
189109,00945 (3360) Spain Meloxicam	EP3090731	9/19/18	Nanoparticulate Meloxicam Formulations	Baudax Bio, Inc.	Issued Expires 2/27/24
189109,00946 (3361) Sweden Meloxicam	EP3090731	9/19/18	Nanoparticulate Meloxicam Formulations	Baudax Bio, Inc.	Issued Expires 2/27/24
189109,00947 (3362) Switzerland Meloxicam	EP3090731	9/19/18	Nanoparticulate Meloxicam Formulations	Baudax Bio, Inc.	Issued Expires 2/27/24
189109,00948 (3363) Netherlands Meloxicam	3090731	9/19/18	Nanoparticulate Meloxicam Formulations	Baudax Bio, Inc.	Issued Expires 2/27/24
189109,00949 (3364) Great Britain Meloxicam	EP3090731	9/19/18	Nanoparticulate Meloxicam Formulations	Baudax Bio, Inc.	Issued Expires 2/27/24
189109,00955 (3367) Hong Kong Meloxicam	19127168.3	7/23/19	Nanoparticulate Meloxicam Formulations	Baudax Bio, Inc.	Pending

Docket No. Country Client Ref. No.	Serial No. Pub. No. Patent No.	Filing Date Pub. Date Issue Date	Title	Owner/Assignee	Status
025 FAMILY					
189109.02500 (3332) United States Meloxicam	62/703,094	7/25/18	Highly Concentrated Meloxicam Compositions	Baudax Bio, Inc.	Abandoned

Docket No. Country	Serial No. Pub. No. Patent No.	Filing Date Pub. Date Issue Date	Title	Applicant(s) Inventor(s)	Status
026 FAMILY					
189109.02600 (3342) United States			Highly Concentrated Meloxicam Formulations	Baudax Bio, Inc.	Not Filed

Docket No. Country	Serial No. Pub. No. Patent No.	Filing Date Pub. Date Issue Date	Title	Owner/Assignee	Status
101 FAMILY					
RECR-001/00US United States	62/652,656	04/04/18	METHODS OF ADMINISTERING INTRAVENOUS MELOXICAM IN A BOLUS DOSE	Baudax Bio, Inc.	Expired
RECR-001/01US United States	16/297,095 20190275054	03/08/19 09/12/19	METHODS OF ADMINISTERING INTRAVENOUS MELOXICAM IN A BOLUS DOSE	Baudax Bio, Inc.	Pending
RECR-001/01WO PCT	PCT/US19/021354 WO20191731715	3/8/19 09/12/19	METHODS OF ADMINISTERING INTRAVENOUS MELOXICAM IN A BOLUS DOSE	Baudax Bio, Inc.	Pending

Docket No. Country	Serial No. Pub. No. Patent No.	Filing Date Pub. Date Issue Date	Title	Owner/Assignee	Status

Docket No. Country	Serial No. Pub. No. Patent No.	Filing Date Pub. Date Issue Date	Title	Owner/Assignee	Status
102 FAMILY					
RECR-002/00US United States	62/640,232	03/08/18	METHOD OF TREATING PAIN IN ELDERLY PATIENTS WITH MILD RENAL IMPAIRMENT	Baudax Bio, Inc.	Expired
RECR-002/01US United States	16/297,020 20190275053	03/08/19 09/12/19	METHOD OF TREATING PAIN IN ELDERLY PATIENTS WITH MILD RENAL IMPAIRMENT	Baudax Bio, Inc.	Pending

Docket No. Country	Serial No. Pub. No. Patent No.	Filing Date Pub. Date Issue Date	Title	Owner/Assignee	Status
103 FAMILY					
RECR-003/00US United States	62/749,407	10/23/18	METHODS OF ADMINISTERING INTRAVENOUS MELOXICAM PRE-OPERATIVELY AND IN COMBINATION WITH OTHER DRUGS	Baudax Bio, Inc.	Expired
RECR-003/01WO PCT	PCT/US2019/057692	10/23/19	METHODS OF ADMINISTERING INTRAVENOUS MELOXICAM PRE-OPERATIVELY AND IN COMBINATION WITH OTHER DRUGS	Baudax Bio, Inc.	Pending

Docket No. Country	Serial No. Pub. No. Patent No.	Filing Date Pub. Date Issue Date	Title	Owner/Assignee	Status
104 FAMILY					
RECR-004/00US United States	62/757,003	11/07/18	METHODS OF TREATING PATIENTS HAVING PLATELET DYSFUNCTION WITH IV MELOXICAM	Baudax Bio, Inc.	Expired
RECR-004/01WO PCT	PCT/US2019/060278 11/07/19		METHODS OF TREATING PATIENTS HAVING PLATELET DYSFUNCTION WITH IV MELOXICAM	Baudax Bio, Inc.	Pending

Patent Licenses

2. Non-Injectable Dexemedetomidine License Agreement dated August 22, 2008, between Recro Pharma, Inc. (now assigned to Recro Ireland Limited) and Orion Corporation.
 - a. First Amendment dated January 17, 2009.
3. Asset Transfer and License Agreement, dated as of April 10, 2015, by and between Alkermes Pharma Ireland Limited and DV Technology LLC.
 - c. First Amendment to Asset Transfer and License Agreement, dated December 23, 2015.
 - d. Second Amendment to Asset Transfer and License Agreement, dated December 20, 2018.
4. License Agreement dated June 30, 2017, by and between Recro Pharma, Inc. and Cornell University, as represented by its Center for Technology Licensing.
 - a. Amendment letter dated October 31, 2018.
 - b. Amendment to License Agreement dated October 21, 2019 by and between Cornell University and Recro Pharma, Inc.

Schedule III

Copyrights and Copyright Licenses

None

Schedule IV

Other Intellectual Property - Domains

agatibio.com

agatipharma.com

agatitherapeutics.com

agatitx.com

aryabiopharma.com

aryabiosciences.com

audaxbio.com

audaxpharm.com

audaxtherapeutics.com

audatx.com

baudaxbio.com

baudaxbioconsulting.com

baudaxconsulting.com

baudaxfieldmaterials.com

baudaxreimbursementhub.com

orcerbio.com

orcerpharma.com

orcertherapeutics.com

orcetx.com